Project description DEENESFRITPL Innovative dendritic selenium-based prodrugs for cancer treatment Reactive oxygen species (ROS) are free radicals containing oxygen that reacts with other cell molecules. Under normal physiological conditions, ROS drive regulatory pathways, and cells control the generation of ROS via scavenging systems. Elevated ROS levels are present in almost all cancer cells, where they promote proliferation. However, high levels of ROS can suppress the growth of cancer cells and kill them via activation of cell-cycle inhibitors. Selenium derivatives show chemotherapeutic potential, based on the ability to act as a pro-oxidant at high dosages. Funded by the Marie Skłodowska-Curie Actions programme, the RUPTURE project aims to develop novel anticancer agents based on selenium-containing dendritic carriers, targeting ROS signalling and inducing cell death. Show the project objective Hide the project objective Objective Elevated rates of reactive oxygen species (ROS) have been detected in almost all cancers, where they promote many aspects of tumour development and progression. The radical generated, the location, as well as the local concentration, are essential for the cellular functions of ROS in cancer. Among redox modulating compounds, selenium derivatives have gained substantial attention due to their promising chemotherapeutic potential, which result from selenium’s ability to act as a pro-oxidant at high dosage. This proposal is intended to develop novel therapeutic agents based on selenium-containing dendrimers, which act as precision carriers with unparalleled structural perfection. These agents, with a plethora of internally queued selenium-selenium bridges will be activated upon the rupturing of the dendritic carriers by external stimuli. It is herein envisioned that RUPTURE can rise to the challenge, acting as cutting-edge prodrugs that will fine-tune intracellular ROS signalling to effectively deprive cells of ROS-induced tumour-promoting events, thereby tipping the balance to ROS-induced apoptotic signalling. Fields of science medical and health sciencesclinical medicineoncology Programme(s) HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme Topic(s) HORIZON-MSCA-2021-PF-01-01 - MSCA Postdoctoral Fellowships 2021 Call for proposal HORIZON-MSCA-2021-PF-01 See other projects for this call Funding Scheme HORIZON-AG-UN - HORIZON Unit Grant Coordinator KUNGLIGA TEKNISKA HOEGSKOLAN Net EU contribution € 206 887,68 Address Brinellvagen 8 100 44 Stockholm Sweden See on map Region Östra Sverige Stockholm Stockholms län Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window EU contribution No data Partners (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all KAROLINSKA INSTITUTET Sweden Net EU contribution € 0,00 Address Nobels vag 5 17177 Stockholm See on map Region Östra Sverige Stockholm Stockholms län Activity type Higher or Secondary Education Establishments Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding No data
